| |||||||
- Description
- Phenotype
- Genes & alleles
- Genotyping
- Health & husbandry
- References
- Purchasing information
- Terms of Use
Description
Strain Information
Type Mutant Stock; Transgenic; Additional information on Genetically Engineered Mutant Mice. Species laboratory mouse H2 Haplotype b Generation B6N2F8pN1 (14-MAR-04) Donating Investigator David Serreze, The Jackson Laboratory Appearance
black
Related Genotype: a/aDescription
These mice carry a T-cell receptor (Tcra-V2, Tcra-J TA31 / Tcrb-V8.1, Tcrb-D, Tcrb-J 2.4) specific for LCMV (lymphocytic choriomeningitis virus), H2-Db . They offer the unique possibility to examine T-cell tolerance to two independent antigens with the same transgenic mouse line. First, T-cell tolerance to LCMV has been studied in transgenic mice carrying the non-cytopathic LCM virus after neonatal infection. Second, the transgenic TCR use the beta-chain variable gene segment Tcrb-V8.1 that reacts preferentially with Mlsa (mixed lymphocyte stimulatory) antigen. Ten to twenty copies of the Tcr transgene are reportedly integrated on the same chromosome. The animals are on a mixed C57BL/6 and DBA/2 background but the MHC haplotype has been checked and found to be H2b.Development
Zinkernagel et al, established a set of LCMV-specific cytotoxic T-cell clones from lethally irradiated B10.BR/SgSn(H-2K reconstituted with T-cell depleted C57BL/10Sn (H-2bbone marrow cells. The rearranged TCR alpha (Tcra-V2 and Tcra-J TA31) and beta (Tcrb-V8.1, TcrB-D, TcrB-J2.4) chain gene sequences from clone P14 were incorporated into transgene contructs regulated by the H-2Kbpromoter and co-injected into B6D2F2 fertilized embryos. 10-20 copies of both the alpha and beta transgenes co-integrated on the same chromosome in male founder number 327. Founder 327 was backcrossed to C57BL/6J for one generation prior to being intercrossed to make this a homozygous strain. This strain is maintained by homozygous sibling matings.
Control Information
| Control | ||
|---|---|---|
| 100006 B6D2F1/J | (approximate) | |
| 000664 C57BL/6J | (approximate) | |
| 000671 DBA/2J | (approximate) | |
| There are no appropriate physiological controls for this mutant strain. However, if you must have a control you may use any of the following strains: B6D2F1/J (Stock No. 100006), C57BL/6J (Stock No. 000664), and DBA/2J (Stock No. 000671). These strains also serve as DNA controls. | ||
| Considerations for Choosing Controls | ||
Related Strains
Strains carrying Tg(TcrLCMV)327Sdz allele
004257 NOD.Cg-Prkdcscid Tg(TcrLCMV)327Sdz/Dvs 004696 NOD.Cg-Tg(TcrLCMV)327Sdz/DvsJ View Strains carrying Tg(TcrLCMV)327Sdz (2 strains)
Phenotype
Phenotype Information
assigned by genotype
Tg(TcrLCMV)327Sdz/0
involves: C57BL/6 * DBA/2
- immune system phenotype
- decreased CD8-positive T cell number (MGI Ref ID J:77696)
- number of CD8+ T cells in spleens of transgenic Mlsa mice is reduced 4-fold compared to uninfected transgenic Mlsb but ~4-fold higher than LCMV-infected Mlsb mice
- decreased T cell proliferation (MGI Ref ID J:77696)
- response of uninfected transgenic Mlsa spleen cells to LCMV is reduced ~3-fold
- decreased double-positive T cell number (MGI Ref ID J:77696)
- numbers of CD4+CD8+ thymocytes are drastically reduced in LCMV-tolerant (carrier) transgenic mice
- defective cytotoxic T cell cytolysis (MGI Ref ID J:77696)
- lysis of LCMV-infected target cells is decreased ~3-fold in uninfected transgenic mice positive for mixed-lymphocyte stimulatory (Mlsa) antigen compared to transgenic mice positive for Mlsb antigen
- LCMV-infected Mlsb show decreased significantly reduced proliferation and specific lysis compared to uninfected transgenic mice
- thymus hypoplasia (MGI Ref ID J:77696)
- numbers of double-positive thymocytes and CD8+ thymocytes are drastically reduced in transgenic mice
- hematopoietic system phenotype
- decreased CD8-positive T cell number (MGI Ref ID J:77696)
- number of CD8+ T cells in spleens of transgenic Mlsa mice is reduced 4-fold compared to uninfected transgenic Mlsb but ~4-fold higher than LCMV-infected Mlsb mice
- decreased T cell proliferation (MGI Ref ID J:77696)
- response of uninfected transgenic Mlsa spleen cells to LCMV is reduced ~3-fold
- decreased double-positive T cell number (MGI Ref ID J:77696)
- numbers of CD4+CD8+ thymocytes are drastically reduced in LCMV-tolerant (carrier) transgenic mice
- thymus hypoplasia (MGI Ref ID J:77696)
- numbers of double-positive thymocytes and CD8+ thymocytes are drastically reduced in transgenic mice
This mouse can be used to support research in many areas including:
Tcra relatedResearch Tools
Immunology and Inflammation Research (T Cell Receptor Transgenics)
Tcrb relatedHematological Research
Immunological Defects
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Research Tools
Cancer Research (specific T cell deficiency)
Hematological Research
Immunological Defects
Immunology and Inflammation Research
CD Antigens, Antigen Receptors, and Histocompatibility Markers
Immunodeficiency
Inflammation
T Cell Receptor Signaling Defects
Genes & Alleles
Gene & Allele Information
| Allele Symbol | Tg(TcrLCMV)327Sdz | ||
|---|---|---|---|
| Allele Name | transgene insertion 327, Birgit Ledermann | ||
| Allele Type | Transgenic (random, expressed) | ||
| Common Name(s) | P14; P14 TCR; P14 TCR-alphabeta (Valpha2Vbeta8.1); P14 TCRValpha2Vbeta8; P14-TCR; TCR LCMV; TCR P14; TCR-Tg; TgTcr; | ||
| Mutation Made By | Rolf Zinkernagel, University of Zurich | ||
| Strain of Origin | (C57BL/6 x DBA/2)F2 | ||
| Expressed Gene | Tcrb, T-cell receptor beta chain, mouse, laboratory | ||
| Expressed Gene | Tcra, T-cell receptor alpha chain, mouse, laboratory | ||
| General Note | Transgenic mice carry a T-cell receptor (Tcra-V2, Tcra-J TA31 / Tcrb-V8.1, Tcrb-D, Tcrb-J 2.4) specific for LCMV (lymphocytic choriomeningitis virus), H2-Db. | ||
| Molecular Note | The transgene carries both Tcra and Tcrb. Ten to twenty copies of the Tcr transgene were reported to have integrated on the same chromosome. At least two transgenic lines are known to exist. Line 327 is the representative line. The second line is 318. [MGI Ref ID J:77696] | ||
Genotyping
Genotyping Information
Genotyping Protocols
Tg(TcrLCMV)327Sdz, STD PCR, vers. 1
Helpful Links
Optimizing PCR Protocols
References
References
Selected Reference(s)
Pircher H; Burki K; Lang R; Hengartner H; Zinkernagel RM. 1989. Tolerance induction in double specific T-cell receptor transgenic mice varies with antigen. Nature 342(6249):559-61. [PubMed: 2573841] [MGI Ref ID J:77696]
Additional References
Kerry SE; Buslepp J; Cramer LA; Maile R; Hensley LL; Nielsen AI; Kavathas P; Vilen BJ; Collins EJ; Frelinger JA. 2003. Interplay between TCR affinity and necessity of coreceptor ligation: high-affinity peptide-MHC/TCR interaction overcomes lack of CD8 engagement. J Immunol 171(9):4493-503. [PubMed: 14568922] [MGI Ref ID J:86195]
Tg(TcrLCMV)327Sdz relatedAichele P; Unsoeld H; Koschella M; Schweier O; Kalinke U; Vucikuja S. 2006. CD8 T cells specific for lymphocytic choriomeningitis virus require type I IFN receptor for clonal expansion. J Immunol 176(8):4525-9. [PubMed: 16585541] [MGI Ref ID J:131168]
Azzam HS; DeJarnette JB; Huang K; Emmons R; Park CS; Sommers CL; El-Khoury D; Shores EW; Love PE. 2001. Fine tuning of TCR signaling by CD5. J Immunol 166(9):5464-72. [PubMed: 11313384] [MGI Ref ID J:106735]
Bachmann MF; Waterhouse P; Speiser DE; McKall-Faienza K; Mak TW; Ohashi PS. 1998. Normal responsiveness of CTLA-4-deficient anti-viral cytotoxic T cells. J Immunol 160(1):95-100. [PubMed: 9551960] [MGI Ref ID J:111103]
Bahl K; Kim SK; Calcagno C; Ghersi D; Puzone R; Celada F; Selin LK; Welsh RM. 2006. IFN-induced attrition of CD8 T cells in the presence or absence of cognate antigen during the early stages of viral infections. J Immunol 176(7):4284-95. [PubMed: 16547266] [MGI Ref ID J:129873]
Beisner DR; Chu IH; Arechiga AF; Hedrick SM; Walsh CM. 2003. The requirements for Fas-associated death domain signaling in mature T cell activation and survival. J Immunol 171(1):247-56. [PubMed: 12817005] [MGI Ref ID J:132831]
Berg-Brown NN; Gronski MA; Jones RG; Elford AR; Deenick EK; Odermatt B; Littman DR; Ohashi PS. 2004. PKCtheta signals activation versus tolerance in vivo. J Exp Med 199(6):743-52. [PubMed: 15024044] [MGI Ref ID J:123989]
Biro J; Wurch A; Potocnik AJ; Falk I; Mossmann H; Eichmann K. 1999. Regulation of T cell receptor (TCR) beta gene expression by CD3 complex signaling in immature thymocytes: implications for TCRbeta allelic exclusion. Proc Natl Acad Sci U S A 96(7):3882-7. [PubMed: 10097132] [MGI Ref ID J:123031]
Blohm U; Potthoff D; van der Kogel AJ; Pircher H. 2006. Solid tumors 'melt' from the inside after successful CD8 T cell attack. Eur J Immunol 36(2):468-77. [PubMed: 16385625] [MGI Ref ID J:113858]
Bosco N; Agenes F; Ceredig R. 2005. Effects of increasing IL-7 availability on lymphocytes during and after lymphopenia-induced proliferation. J Immunol 175(1):162-70. [PubMed: 15972643] [MGI Ref ID J:100611]
Boyman O; Ramsey C; Kim DM; Sprent J; Surh CD. 2008. IL-7/anti-IL-7 mAb complexes restore T cell development and induce homeostatic T Cell expansion without lymphopenia. J Immunol 180(11):7265-75. [PubMed: 18490726] [MGI Ref ID J:136336]
Brabb T; von Dassow P; Ordonez N; Schnabel B; Duke B; Goverman J. 2000. In situ tolerance within the central nervous system as a mechanism for preventing autoimmunity. J Exp Med 192(6):871-80. [PubMed: 10993917] [MGI Ref ID J:107210]
Brehm MA; Daniels KA; Welsh RM. 2005. Rapid production of TNF-alpha following TCR engagement of naive CD8 T cells. J Immunol 175(8):5043-9. [PubMed: 16210607] [MGI Ref ID J:119124]
Calzascia T; Pellegrini M; Lin A; Garza KM; Elford AR; Shahinian A; Ohashi PS; Mak TW. 2008. CD4 T cells, lymphopenia, and IL-7 in a multistep pathway to autoimmunity. Proc Natl Acad Sci U S A 105(8):2999-3004. [PubMed: 18287017] [MGI Ref ID J:132821]
Chandele A; Joshi NS; Zhu J; Paul WE; Leonard WJ; Kaech SM. 2008. Formation of IL-7Ralphahigh and IL-7Ralphalow CD8 T cells during infection is regulated by the opposing functions of GABPalpha and Gfi-1. J Immunol 180(8):5309-19. [PubMed: 18390712] [MGI Ref ID J:134240]
Christensen JE; Nansen A; Moos T; Lu B; Gerard C; Christensen JP; Thomsen AR. 2004. Efficient T-cell surveillance of the CNS requires expression of the CXC chemokine receptor 3. J Neurosci 24(20):4849-58. [PubMed: 15152045] [MGI Ref ID J:96905]
Crompton T; Moore M; MacDonald HR; Malissen B. 1994. Double-negative thymocyte subsets in CD3 zeta chain-deficient mice: absence of HSA+CD44-CD25- cells. Eur J Immunol 24(8):1903-7. [PubMed: 7520000] [MGI Ref ID J:112990]
Davidson D; Schraven B; Veillette A. 2007. PAG-associated FynT regulates calcium signaling and promotes anergy in T lymphocytes. Mol Cell Biol 27(5):1960-73. [PubMed: 17210649] [MGI Ref ID J:118860]
Ehl S; Hombach J; Aichele P; Hengartner H; Zinkernagel RM. 1997. Bystander activation of cytotoxic T cells: studies on the mechanism and evaluation of in vivo significance in a transgenic mouse model. J Exp Med 185(7):1241-51. [PubMed: 9104811] [MGI Ref ID J:107413]
Ferrero I; Grosjean F; Fiorini E; Macdonald HR. 2007. A critical lineage-nonspecific role for pTalpha in mediating allelic and isotypic exclusion in TCRbeta-transgenic mice. Eur J Immunol 37(11):3220-8. [PubMed: 17918204] [MGI Ref ID J:126317]
Ford MS; Young KJ; Zhang Z; Ohashi PS; Zhang L. 2002. The immune regulatory function of lymphoproliferative double negative T cells in vitro and in vivo. J Exp Med 196(2):261-7. [PubMed: 12119351] [MGI Ref ID J:120698]
Fung-Leung WP; Wallace VA; Gray D; Sha WC; Pircher H; Teh HS; Loh DY; Mak TW. 1993. CD8 is needed for positive selection but differentially required for negative selection of T cells during thymic ontogeny. Eur J Immunol 23(1):212-6. [PubMed: 8419174] [MGI Ref ID J:112993]
Gronski MA; Boulter JM; Moskophidis D; Nguyen LT; Holmberg K; Elford AR; Deenick EK; Kim HO; Penninger JM; Odermatt B; Gallimore A; Gascoigne NR; Ohashi PS. 2004. TCR affinity and negative regulation limit autoimmunity. Nat Med 10(11):1234-9. [PubMed: 15467726] [MGI Ref ID J:94025]
Gu X; Laouar A; Wan J; Daheshia M; Lieberman J; Yokoyama WM; Katz HR; Manjunath N. 2003. The gp49B1 inhibitory receptor regulates the IFN-gamma responses of T cells and NK cells. J Immunol 170(8):4095-101. [PubMed: 12682239] [MGI Ref ID J:134418]
Gu Y; Chae HD; Siefring JE; Jasti AC; Hildeman DA; Williams DA. 2006. RhoH GTPase recruits and activates Zap70 required for T cell receptor signaling and thymocyte development. Nat Immunol 7(11):1182-1190. [PubMed: 17028588] [MGI Ref ID J:113565]
Hermans IF; Ritchie DS; Daish A; Yang J; Kehry MR; Ronchese F. 1999. Impaired ability of MHC class II-/- dendritic cells to provide tumor protection is rescued by CD40 ligation. J Immunol 163(1):77-81. [PubMed: 10384102] [MGI Ref ID J:55653]
Iannacone M; Sitia G; Isogawa M; Whitmire JK; Marchese P; Chisari FV; Ruggeri ZM; Guidotti LG. 2008. Platelets prevent IFN-alpha/beta-induced lethal hemorrhage promoting CTL-dependent clearance of lymphocytic choriomeningitis virus. Proc Natl Acad Sci U S A 105(2):629-34. [PubMed: 18184798] [MGI Ref ID J:131089]
Intlekofer AM; Takemoto N; Kao C; Banerjee A; Schambach F; Northrop JK; Shen H; Wherry EJ; Reiner SL. 2007. Requirement for T-bet in the aberrant differentiation of unhelped memory CD8+ T cells. J Exp Med 204(9):2015-21. [PubMed: 17698591] [MGI Ref ID J:126087]
Intlekofer AM; Takemoto N; Wherry EJ; Longworth SA; Northrup JT; Palanivel VR; Mullen AC; Gasink CR; Kaech SM; Miller JD; Gapin L; Ryan K; Russ AP; Lindsten T; Orange JS; Goldrath AW; Ahmed R; Reiner SL. 2005. Effector and memory CD8+ T cell fate coupled by T-bet and eomesodermin. Nat Immunol 6(12):1236-44. [PubMed: 16273099] [MGI Ref ID J:112679]
Jeon MS; Atfield A; Venuprasad K; Krawczyk C; Sarao R; Elly C; Yang C; Arya S; Bachmaier K; Su L; Bouchard D; Jones R; Gronski M; Ohashi P; Wada T; Bloom D; Fathman CG; Liu YC; Penninger JM. 2004. Essential role of the E3 ubiquitin ligase Cbl-b in T cell anergy induction. Immunity 21(2):167-77. [PubMed: 15308098] [MGI Ref ID J:93595]
Kagi D; Ho A; Odermatt B; Zakarian A; Ohashi PS; Mak TW. 1999. TNF receptor 1-dependent beta cell toxicity as an effector pathway in autoimmune diabetes. J Immunol 162(8):4598-605. [PubMed: 10201999] [MGI Ref ID J:120458]
Kaufmann M; Blaser C; Takashima S; Schwartz-Albiez R; Tsuji S; Pircher H. 1999. Identification of an alpha2,6-sialyltransferase induced early after lymphocyte activation. Int Immunol 11(5):731-8. [PubMed: 10330278] [MGI Ref ID J:56212]
Kirberg J; Bosco N; Deloulme JC; Ceredig R; Agenes F. 2008. Peripheral T lymphocytes recirculating back into the thymus can mediate thymocyte positive selection. J Immunol 181(2):1207-14. [PubMed: 18606674] [MGI Ref ID J:137464]
Krawczyk C; Oliveira-dos-Santos A; Sasaki T; Griffiths E; Ohashi PS; Snapper S; Alt F; Penninger JM. 2002. Vav1 controls integrin clustering and MHC/peptide-specific cell adhesion to antigen-presenting cells. Immunity 16(3):331-43. [PubMed: 11911819] [MGI Ref ID J:111206]
Lang KS; Georgiev P; Recher M; Navarini AA; Bergthaler A; Heikenwalder M; Harris NL; Junt T; Odermatt B; Clavien PA; Pircher H; Akira S; Hengartner H; Zinkernagel RM. 2006. Immunoprivileged status of the liver is controlled by Toll-like receptor 3 signaling. J Clin Invest 116(9):2456-63. [PubMed: 16955143] [MGI Ref ID J:114665]
Lang KS; Recher M; Junt T; Navarini AA; Harris NL; Freigang S; Odermatt B; Conrad C; Ittner LM; Bauer S; Luther SA; Uematsu S; Akira S; Hengartner H; Zinkernagel RM. 2005. Toll-like receptor engagement converts T-cell autoreactivity into overt autoimmune disease. Nat Med 11(2):138-45. [PubMed: 15654326] [MGI Ref ID J:96036]
Laouar A; Haridas V; Vargas D; Zhinan X; Chaplin D; van Lier RA; Manjunath N. 2005. CD70+ antigen-presenting cells control the proliferation and differentiation of T cells in the intestinal mucosa. Nat Immunol 6(7):698-706. [PubMed: 15937486] [MGI Ref ID J:99148]
Leduc I; Karsunky H; Mathieu N; Schmidt T; Verthuy C; Ferrier P; Moroy T. 2000. The Pim-1 kinase stimulates maturation of TCRbeta-deficient T cell progenitors: implications for the mechanism of Pim-1 action. Int Immunol 12(10):1389-96. [PubMed: 11007756] [MGI Ref ID J:110498]
Lee MS; Wogensen L; Shizuru J; Oldstone MB; Sarvetnick N. 1994. Pancreatic islet production of murine interleukin-10 does not inhibit immune-mediated tissue destruction. J Clin Invest 93(3):1332-8. [PubMed: 8132775] [MGI Ref ID J:17133]
Liadis N; Murakami K; Eweida M; Elford AR; Sheu L; Gaisano HY; Hakem R; Ohashi PS; Woo M. 2005. Caspase-3-Dependent {beta}-Cell Apoptosis in the Initiation of Autoimmune Diabetes Mellitus. Mol Cell Biol 25(9):3620-9. [PubMed: 15831467] [MGI Ref ID J:97650]
Liao MJ; Zhang XX; Hill R; Gao J; Qumsiyeh MB; Nichols W; Van Dyke T. 1998. No requirement for V(D)J recombination in p53-deficient thymic lymphoma. Mol Cell Biol 18(6):3495-501. [PubMed: 9584189] [MGI Ref ID J:47667]
Magnan A; Di Bartolo V; Mura AM; Boyer C; Richelme M; Lin YL; Roure A; Gillet A; Arrieumerlou C; Acuto O; Malissen B; Malissen M. 2001. T cell development and T cell responses in mice with mutations affecting tyrosines 292 or 315 of the ZAP-70 protein tyrosine kinase. J Exp Med 194(4):491-505. [PubMed: 11514605] [MGI Ref ID J:71099]
Mak TW; Hakem A; McPherson JP; Shehabeldin A; Zablocki E; Migon E; Duncan GS; Bouchard D; Wakeham A; Cheung A; Karaskova J; Sarosi I; Squire J; Marth J; Hakem R. 2000. Brcal required for T cell lineage development but not TCR loci rearrangement. Nat Immunol 1(1):77-82. [PubMed: 10881179] [MGI Ref ID J:63282]
Marquez ME; Ellmeier W; Sanchez-Guajardo V; Freitas AA; Acuto O; Di Bartolo V. 2005. CD8 T cell sensory adaptation dependent on TCR avidity for self-antigens. J Immunol 175(11):7388-97. [PubMed: 16301646] [MGI Ref ID J:122169]
Matter M; Mumprecht S; Pinschewer DD; Pavelic V; Yagita H; Krautwald S; Borst J; Ochsenbein AF. 2005. Virus-induced polyclonal B cell activation improves protective CTL memory via retained CD27 expression on memory CTL. Eur J Immunol 35(11):3229-39. [PubMed: 16231287] [MGI Ref ID J:113775]
Matter M; Odermatt B; Yagita H; Nuoffer JM; Ochsenbein AF. 2006. Elimination of chronic viral infection by blocking CD27 signaling. J Exp Med 203(9):2145-55. [PubMed: 16923852] [MGI Ref ID J:124567]
Matter M; Pavelic V; Pinschewer DD; Mumprecht S; Eschli B; Giroglou T; von Laer D; Ochsenbein AF. 2007. Decreased tumor surveillance after adoptive T-cell therapy. Cancer Res 67(15):7467-76. [PubMed: 17671217] [MGI Ref ID J:123912]
Matter MS; Claus C; Ochsenbein AF. 2008. CD4(+) T cell help improves CD8(+) T cell memory by retained CD27 expression. Eur J Immunol 38(7):1847-56. [PubMed: 18506879] [MGI Ref ID J:137313]
Mazo IB; Honczarenko M; Leung H; Cavanagh LL; Bonasio R; Weninger W; Engelke K; Xia L; McEver RP; Koni PA; Silberstein LE; von Andrian UH. 2005. Bone marrow is a major reservoir and site of recruitment for central memory CD8+ T cells. Immunity 22(2):259-70. [PubMed: 15723813] [MGI Ref ID J:96675]
Miyakoda M; Kimura D; Yuda M; Chinzei Y; Shibata Y; Honma K; Yui K. 2008. Malaria-specific and nonspecific activation of CD8+ T cells during blood stage of Plasmodium berghei infection. J Immunol 181(2):1420-8. [PubMed: 18606696] [MGI Ref ID J:137658]
Montoya M; Edwards MJ; Reid DM; Borrow P. 2005. Rapid activation of spleen dendritic cell subsets following lymphocytic choriomeningitis virus infection of mice: analysis of the involvement of type 1 IFN. J Immunol 174(4):1851-61. [PubMed: 15699111] [MGI Ref ID J:96536]
Nanjappa SG; Walent JH; Morre M; Suresh M. 2008. Effects of IL-7 on memory CD8 T cell homeostasis are influenced by the timing of therapy in mice. J Clin Invest 118(3):1027-39. [PubMed: 18246202] [MGI Ref ID J:135264]
Nil A; Firat E; Sobek V; Eichmann K; Niedermann G. 2004. Expression of housekeeping and immunoproteasome subunit genes is differentially regulated in positively and negatively selecting thymic stroma subsets. Eur J Immunol 34(10):2681-9. [PubMed: 15368284] [MGI Ref ID J:115499]
Ohashi PS; Oehen S; Buerki K; Pircher H; Ohashi CT; Odermatt B; Malissen B; Zinkernagel RM; Hengartner H. 1991. Ablation of 'tolerance' and induction of diabetes by virus infection in viral antigen transgenic mice. Cell 65(2):305-17. [PubMed: 1901764] [MGI Ref ID J:81285]
Penninger JM; Sirard C; Mittrucker HW; Chidgey A; Kozieradzki I; Nghiem M; Hakem A; Kimura T; Timms E; Boyd R; Taniguchi T; Matsuyama T; Mak TW. 1997. The interferon regulatory transcription factor IRF-1 controls positive and negative selection of CD8+ thymocytes. Immunity 7(2):243-54. [PubMed: 9285409] [MGI Ref ID J:111439]
Posevitz V; Arndt B; Krieger T; Warnecke N; Schraven B; Simeoni L. 2008. Regulation of T cell homeostasis by the transmembrane adaptor protein SIT. J Immunol 180(3):1634-42. [PubMed: 18209059] [MGI Ref ID J:131507]
Puglielli MT; Zajac AJ; van der Most RG; Dzuris JL; Sette A; Altman JD; Ahmed R. 2001. In vivo selection of a lymphocytic choriomeningitis virus variant that affects recognition of the GP33-43 epitope by H-2Db but not H-2Kb. J Virol 75(11):5099-107. [PubMed: 11333891] [MGI Ref ID J:69366]
Ruedl C; Storni T; Lechner F; Bachi T; Bachmann MF. 2002. Cross-presentation of virus-like particles by skin-derived CD8(-) dendritic cells: a dispensable role for TAP. Eur J Immunol 32(3):818-25. [PubMed: 11870626] [MGI Ref ID J:115370]
Serreze DV; Johnson EA; Chapman HD; Graser RT; Marron MP; DiLorenzo TP; Silveira P; Yoshimura Y; Nathenson SG; Joyce S. 2001. Autoreactive diabetogenic T-cells in NOD mice can efficiently expand from a greatly reduced precursor pool. Diabetes 50(9):1992-2000. [PubMed: 11522664] [MGI Ref ID J:71050]
Simeoni L; Posevitz V; Kolsch U; Meinert I; Bruyns E; Pfeffer K; Reinhold D; Schraven B. 2005. The transmembrane adapter protein SIT regulates thymic development and peripheral T-cell functions. Mol Cell Biol 25(17):7557-68. [PubMed: 16107703] [MGI Ref ID J:100408]
Sinclair LV; Finlay D; Feijoo C; Cornish GH; Gray A; Ager A; Okkenhaug K; Hagenbeek TJ; Spits H; Cantrell DA. 2008. Phosphatidylinositol-3-OH kinase and nutrient-sensing mTOR pathways control T lymphocyte trafficking. Nat Immunol 9(5):513-21. [PubMed: 18391955] [MGI Ref ID J:134510]
Sun G; Liu X; Mercado P; Jenkinson SR; Kypriotou M; Feigenbaum L; Galera P; Bosselut R. 2005. The zinc finger protein cKrox directs CD4 lineage differentiation during intrathymic T cell positive selection. Nat Immunol 6(4):373-81. [PubMed: 15750595] [MGI Ref ID J:97610]
Sun JC; Williams MA; Bevan MJ. 2004. CD4+ T cells are required for the maintenance, not programming, of memory CD8+ T cells after acute infection. Nat Immunol 5(9):927-33. [PubMed: 15300249] [MGI Ref ID J:92169]
Suzuki H; Wu J; Hossain K; Ohhata T; Du J; Akhand AA; Hayakawa A; Kimura H; Hagiwara M; Nakashima I. 2003. Involvement of MKK6 in TCRalphabeta(int)CD69lo: a target population for apoptotic cell death in thymocytes. FASEB J 17(11):1538-40. [PubMed: 12824301] [MGI Ref ID J:100093]
Suzuki N; Suzuki S; Millar DG; Unno M; Hara H; Calzascia T; Yamasaki S; Yokosuka T; Chen NJ; Elford AR; Suzuki J; Takeuchi A; Mirtsos C; Bouchard D; Ohashi PS; Yeh WC; Saito T. 2006. A critical role for the innate immune signaling molecule IRAK-4 in T cell activation. Science 311(5769):1927-32. [PubMed: 16574867] [MGI Ref ID J:107198]
Takemoto N; Intlekofer AM; Northrup JT; Wherry EJ; Reiner SL. 2006. Cutting Edge: IL-12 inversely regulates T-bet and eomesodermin expression during pathogen-induced CD8+ T cell differentiation. J Immunol 177(11):7515-9. [PubMed: 17114419] [MGI Ref ID J:140606]
Tarakhovsky A; Kanner SB; Hombach J; Ledbetter JA; Muller W; Killeen N; Rajewsky K. 1995. A role for CD5 in TCR-mediated signal transduction and thymocyte selection. Science 269(5223):535-7. [PubMed: 7542801] [MGI Ref ID J:89249]
Uehara S; Grinberg A; Farber JM; Love PE. 2002. A role for CCR9 in T lymphocyte development and migration. J Immunol 168(6):2811-9. [PubMed: 11884450] [MGI Ref ID J:110846]
Ugolini S; Arpin C; Anfossi N; Walzer T; Cambiaggi A; Forster R; Lipp M; Toes RE; Melief CJ; Marvel J; Vivier E. 2001. Involvement of inhibitory NKRs in the survival of a subset of memory-phenotype CD8+ T cells. Nat Immunol 2(5):430-5. [PubMed: 11323697] [MGI Ref ID J:133096]
Unsoeld H; Mueller K; Schleicher U; Bogdan C; Zwirner J; Voehringer D; Pircher H. 2007. Abrogation of CCL21 chemokine function by transgenic over-expression impairs T cell immunity to local infections. Int Immunol 19(11):1281-9. [PubMed: 17914120] [MGI Ref ID J:125752]
Wall EM; Milne K; Martin ML; Watson PH; Theiss P; Nelson BH. 2007. Spontaneous mammary tumors differ widely in their inherent sensitivity to adoptively transferred T cells. Cancer Res 67(13):6442-50. [PubMed: 17616705] [MGI Ref ID J:122846]
Wallace VA; Kawai K; Levelt CN; Kishihara K; Molina T; Timms E; Pircher H; Penninger J; Ohashi PS; Eichmann K; Mak TW. 1995. T lymphocyte development in p56lck deficient mice: allelic exclusion of the TcR beta locus is incomplete but thymocyte development is not restored by TcR beta or TcR alpha beta transgenes. Eur J Immunol 25(5):1312-8. [PubMed: 7774634] [MGI Ref ID J:25742]
Wallace VA; Penninger JM; Kishihara K; Timms E; Shahinian A; Pircher H; Kundig TM; Ohashi PS; Mak TW. 1997. Alterations in the level of CD45 surface expression affect the outcome of thymic selection. J Immunol 158(7):3205-14. [PubMed: 9120275] [MGI Ref ID J:110837]
Wang B; Sharma A; Maile R; Saad M; Collins EJ; Frelinger JA. 2002. Peptidic termini play a significant role in TCR recognition. J Immunol 169(6):3137-45. [PubMed: 12218131] [MGI Ref ID J:120444]
Waterhouse P; Bachmann MF; Penninger JM; Ohashi PS; Mak TW. 1997. Normal thymic selection, normal viability and decreased lymphoproliferation in T cell receptor-transgenic CTLA-4-deficient mice. Eur J Immunol 27(8):1887-92. [PubMed: 9295023] [MGI Ref ID J:42659]
Wingender G; Berg M; Jungerkes F; Diehl L; Sullivan BA; Kronenberg M; Limmer A; Knolle PA. 2006. Immediate antigen-specific effector functions by TCR-transgenic CD8+ NKT cells. Eur J Immunol 36(3):570-82. [PubMed: 16506291] [MGI Ref ID J:114826]
Yan J; Parekh VV; Mendez-Fernandez Y; Olivares-Villagomez D; Dragovic S; Hill T; Roopenian DC; Joyce S; Van Kaer L. 2006. In vivo role of ER-associated peptidase activity in tailoring peptides for presentation by MHC class Ia and class Ib molecules. J Exp Med 203(3):647-59. [PubMed: 16505142] [MGI Ref ID J:122479]
Zhang M; Park SM; Wang Y; Shah R; Liu N; Murmann AE; Wang CR; Peter ME; Ashton-Rickardt PG. 2006. Serine protease inhibitor 6 protects cytotoxic T cells from self-inflicted injury by ensuring the integrity of cytotoxic granules. Immunity 24(4):451-61. [PubMed: 16618603] [MGI Ref ID J:113349]
Zhang ZX; Yang L; Young KJ; DuTemple B; Zhang L. 2000. Identification of a previously unknown antigen-specific regulatory T cell and its mechanism of suppression. Nat Med 6(7):782-9. [PubMed: 10888927] [MGI Ref ID J:118729]
Zimmermann C; Rawiel M; Blaser C; Kaufmann M; Pircher H. 1996. Homeostatic regulation of CD8+ T cells after antigen challenge in the absence of Fas (CD95). Eur J Immunol 26(12):2903-10. [PubMed: 8977284] [MGI Ref ID J:37076]
Health & husbandry
Health & Colony Maintenance Information
Currently there no information available for this strain. This may be due to the supply level of this strain.
Purchasing information
Pricing, Supply Level & Notes, Controls, General Terms & Conditions
Pricing
| Pricing for USA, Canada and Mexico shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $1900.00 Cryopreserved Embryos Fee $1600.00
Additional Supply Details
| Pricing for International shipping destinations |
|
*Price(s) in US dollars ($)
Weeks of Age Price* Gender Cryorecovery Fee $2470.00 Cryopreserved Embryos Fee $2080.00
Additional Supply Details
|
|
|
Supply Details
| Standard Supply | Repository-Cryopreserved. Must Be Recovered. Please refer to pricing and supply notes for further information. |
|---|---|
| Supply Notes |
|
Control Information
| Control | ||
|---|---|---|
| 100006 B6D2F1/J | (approximate) | |
| 000664 C57BL/6J | (approximate) | |
| 000671 DBA/2J | (approximate) | |
| There are no appropriate physiological controls for this mutant strain. However, if you must have a control you may use any of the following strains: B6D2F1/J (Stock No. 100006), C57BL/6J (Stock No. 000664), and DBA/2J (Stock No. 000671). These strains also serve as DNA controls. | ||
| Considerations for Choosing Controls | ||
| USA, Canada and Mexico - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
| International - Control Pricing Information for Genetically Engineered Mutant Strains. | ||
General Terms and Conditions
See Terms of Use
The Jackson Laboratory's Genotype Promise
The Jackson Laboratory has rigorous genetic quality control and mutant gene genotyping programs to ensure the genetic background of JAX® Mice strains as well as the genotypes of strains with identified molecular mutations. JAX® Mice strains are only made available to researchers after meeting our standards. However, the phenotype of each strain may not be fully characterized and/or captured in the strain data sheets. Therefore, we cannot guarantee a strain's phenotype will meet all expectations. To ensure that JAX® Mice will meet the needs of individual research projects or when requesting a strain that is new to your research, we suggest ordering and performing tests on a small number of mice to determine suitability for your particular project.Ordering and Purchasing Information
Purchasing Information
JAX® Mice Orders
Surgical Services
Contact Information
Orders & Technical Support
Tel: 800.422.6423 or 207.288.5845
Fax: 207.288.6150
Technical Support Email Form
Terms of Use
Terms of Use
General Terms and Conditions
Contact information
General inquiries
Contracts Administration
| phone: | 207-288-6470 |
| fax: | 207-288-6655 |
JAX® Mice & Services Conditions of Use
“Each recipient institution, including its employees and other researchers under its control (RECIPIENT), of mice or services using mice from The Jackson Laboratory (TJL) agrees that such mice, descendants of those mice derived by inbreeding or crossbreeding, including unmodified derivatives of those mice or their descendants (“MICE”) shall not be: (i) used for any purpose other than the internal research of the RECIPIENT, (ii) sold or otherwise provided to any third party for any use, or (iii) provided to any agent or other third party to provide breeding or other services with respect to MICE. Acceptance of MICE from TJL shall be deemed agreement by RECIPIENT to these conditions, and departure from these conditions requires The Jackson Laboratory’s prior written authorization.”No Warranty
MICE, PRODUCTS AND SERVICES ARE PROVIDED “AS IS”. THE LABORATORY EXTENDS NO WARRANTIES OF ANY KIND, EITHER EXPRESS, IMPLIED, OR STATUTORY, WITH RESPECT TO MICE, PRODUCTS OR SERVICES, INCLUDING ANY IMPLIED WARRANTY OF MERCHANTABILITY OR FITNESS FOR A PARTICULAR PURPOSE, OR ANY WARRANTY OF NON-INFRINGEMENT OF ANY PATENT, TRADEMARK, OR OTHER INTELLECTUAL PROPERTY RIGHTS.
In case of dissatisfaction for a valid reason and claimed in writing by a purchaser within ninety (90) days of receipt of MICE, products or services, The Jackson Laboratory will, at its option, provide credit or replacement for the MICE or product received or the services provided.
No Liability
In no event shall The Jackson Laboratory, its trustees, directors, officers, employees, and affiliates be liable for any causes of action or damages, including any direct, indirect, special, or consequential damages, arising out of the provision of MICE, products or services, including economic damage or injury to property and lost profits, and including any damage arising from acts or negligence on the part of The Jackson Laboratory, its agents or employees. In purchasing or receiving MICE, products or services from The Jackson Laboratory, purchaser or recipient, or any party claiming by or through them, expressly releases and discharges The Jackson Laboratory from all such causes of action or damages, and further agrees to defend and indemnify The Jackson Laboratory from any costs or damages arising out of any third party claims.
MICE and biological materials are to be used in a safe manner and in accordance with all applicable governmental rules and regulations.
The foregoing represents the General Terms and Conditions applicable to The Jackson Laboratory’s MICE, products and services. In addition, special terms and conditions of sale of certain MICE, products and services may be set forth separately in The Jackson Laboratory web pages, catalogs, price lists, contracts, and/or other documents, and these special terms and conditions shall also govern the sale of these MICE, products and services by The Jackson Laboratory, and by its licensees and distributors.
Acceptance of delivery of MICE, products or services shall be deemed agreement to these terms and conditions. No purchase order or other document transmitted by purchaser or recipient that may modify the terms and conditions hereof, shall be in any way binding on The Jackson Laboratory, and instead the terms and conditions set forth herein, including any special terms and conditions set forth separately, shall govern the sale of MICE, products services by The Jackson Laboratory.